Patents Examined by David Schreiber
  • Patent number: 10304423
    Abstract: The present indention provides a stringed musical instrument comprising; a substantially hollow body portion containing an audio system comprising an amplifier; at least one loudspeaker electrically connected to the audio amplifier; an audio interface for electrically connecting to a smart device and a power supply electrically connected to the audio system; a neck sub-assembly including: a neck; playing strings extending lengthwise along the neck; a bridge attached to the neck over which the strings are stretched, and tensioning means by which the strings are held tensioned; and a docking station whereby, in use, a smart device may be removably secured to the instrument and electrically connected to the audio system.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: May 28, 2019
    Assignee: FUSION MUSICTECH IP PTY LTD.
    Inventor: David McAuld
  • Patent number: 5641864
    Abstract: Methods are provided for the replication and amplification of RNA sequences by thermoactive DNA polymerases. In a preferred embodiment, high temperature reverse transcription is coupled to nucleic acid amplification in a one tube, one enzyme procedure using a thermostable DNA polymerase. Methods for eliminating carry over contamination of amplifications due to prior reverse transcription reactions are also provided.
    Type: Grant
    Filed: September 22, 1994
    Date of Patent: June 24, 1997
    Assignee: Hoffman-La Roche Inc.
    Inventor: David H. Gelfand
  • Patent number: 5618703
    Abstract: Methods are provided for distinguishing between RNA and DNA templates in an amplification reaction. In a preferred embodiment of the invention, the amplification reaction is a PCR and the reaction is catalyzed by a thermostable DNA polymerase or both reverse transcription and amplification of a target RNA. The invention particularly relates to selective amplification of RNA in the presence of homologous DNA, for example, HIV nucleic acids.
    Type: Grant
    Filed: February 22, 1994
    Date of Patent: April 8, 1997
    Assignee: Hoffmann-La Roche Inc.
    Inventors: David H. Gelfand, Thomas W. Myers
  • Patent number: 5597911
    Abstract: Nucleic acid fragments have been obtained from the genome of mycobacteria, and applications of the nucleic acid fragments in the diagnosis of mycobacterial infections are described. More particularly, the present invention concerns an isolated polynucleotide of the formula:5'-(SEQ ID NO: 1)-(formula III)-(SEQ ID NO: 2)-3'where formula III represents a polynucleotide containing nucleotides 343-1152 of SEQ ID NO: 3. Primers and probes based on the isolated polynucleotide, DNA complementary to any of the polynucleotides, primers or probes, a method of detecting and identifying at least one species or group of mycobacteria, and a kit, box, or coordinated set for conducting the method are also described.
    Type: Grant
    Filed: April 14, 1992
    Date of Patent: January 28, 1997
    Assignee: Institut Pasteur
    Inventors: Jean-Luc Guesdon, Dominique Thierry, Agn es Ullmann, Brigitte Gicquel, Anne Brisson-Noel
  • Patent number: 5595880
    Abstract: The present invention provides an isolated nucleic acid molecule encoding an .alpha..sub.2B -adrenergic receptor, and an isolated protein which is a human .alpha..sub.2B -adrenergic receptor. The invention also provides vectors comprising DNA molecules encoding a human .alpha..sub.2B -adrenergic receptor, and vectors adapted for expression of the .alpha.2b.sub.2B -adrenergic receptor in bacterial, yeast, or mammalian cells. In addition, the invention provides a DNA probe useful for detecting nucleic acid encoding the .alpha.2b.sub.2B -adrenergic receptor, a method for determining whether a ligand which is not known to be capable of binding to the .alpha.2b.sub.2B -adrenergic receptor can bind to the .alpha..sub.2B -adrenergic receptor on the surface of a cell, and a method of screening drugs to identify drugs to identify drugs which specifically interact with, and bind to, the .alpha..sub.2B -adrenergic receptor. The invention herein also concern an antibody directed to the human .alpha..sub.
    Type: Grant
    Filed: October 22, 1992
    Date of Patent: January 21, 1997
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Richard L. Weinshank, Paul R. Hartig
  • Patent number: 5565323
    Abstract: The present invention relates to genetic mutations in mitochondrial cytochrome oxidase genes that segregate with Alzheimer's disease (AD). The invention provides methods for detecting such mutations, as a diagnostic for Alzheimer's Disease, either before or after the onset clinical symptoms. The invention further provides treatment of cytochrome oxidase dysfunction.
    Type: Grant
    Filed: March 30, 1994
    Date of Patent: October 15, 1996
    Assignee: MitoKor
    Inventors: W. Davis Parker, Corinna Herrnstadt
  • Patent number: 5552279
    Abstract: Nucleic acid probes are described for detecting the principle etiological agent of primary atypical pneumonia, Mycoplasma pneumoniae, or, optionally, Mycoplasma pneumoniae and Mycoplasma genitalium. Said probes are complementary to ribonucleic acid sequences found in these mycoplasmas and absent from other mycoplasma, other bacterial, animal, or plant genomes. As such, these probes can detect the rRNA, rDNA, or polymerase chain reaction amplification products from these mycoplasma species. This set of probes, plus the described amplification primers, circumscribe a method for detecting the etiological agents of atypical pneumonia, and for making a clinical diagnosis of this disease. This set of probes also circumscribes a method for identification of these infectious agents in culture media enrichments inoculated from clinical samples.
    Type: Grant
    Filed: July 29, 1994
    Date of Patent: September 3, 1996
    Assignee: Amoco Corporation
    Inventors: William G. Weisburg, Dale A. Pelletier
  • Patent number: 5547838
    Abstract: An improved method is disclosed for diagnosing the presence of a chromosomal translocation characteristic of acute myelogenous leukemia. Nucleic acid molecules that may be used in this improved method are described.
    Type: Grant
    Filed: April 19, 1994
    Date of Patent: August 20, 1996
    Assignee: Life Technologies, Inc.
    Inventors: Paul E. Nisson, Nicoletta Sacchi
  • Patent number: 5545540
    Abstract: The invention provides a process for amplification of specific nucleic acid sequences based upon the separation of nucleic acid strands by an electromagnetic field. This means of separation allows the use of mesophilic polymerases in the amplification process, thereby increasing the speed and fidelity of the amplification process.
    Type: Grant
    Filed: January 19, 1995
    Date of Patent: August 13, 1996
    Assignee: Gamera Bioscience Corporation
    Inventor: Alec Mian
  • Patent number: 5541311
    Abstract: A means for cleaving a nucleic acid cleavage structure in a site-specific manner is disclosed. A cleaving enzyme having 5' nuclease activity without interfering nucleic acid synthetic ability is employed as the basis of a novel method of detection of specific nucleic acid sequences. Cleaving enzymes are produced through the use of novel DNA sequences which encode novel thermostable polymerases.
    Type: Grant
    Filed: June 4, 1993
    Date of Patent: July 30, 1996
    Assignee: Third Wave Technologies, Inc.
    Inventors: James E. Dahlberg, Victor I. Lyamichev, Mary Ann D. Brow
  • Patent number: 5525717
    Abstract: A nucleotide sequence characteristic of Neisseria gonorrhoeae is disclosed. The sequence can be the basis for hybridization type, nucleic acid-based, rapid, in vitro diagnostic assays. The unique nature of the sequence makes it possible to clearly discriminate N. gonorrhoeae from other Neisseria species thus eliminating or substantially reducing the number of false positive readings. A 350 base pair N. gonorrhoeae DNA restriction fragment was cloned after subtractive hybridization to Neisseria meningitidis DNA. In further cloning experiments the sequences adjacent to the original 350 base pair fragment were determined. A portion of this sequence was shown to detect 105 of 106 N. gonorrhoeae strains and no other Neisseria species. In addition to use as detection probes, all or portions of the nucleotide sequence can be used as a ligand for the sandwich capture of N. gonorrhoeae sequences and as primers for in vitro amplification of N. gonorrhoeae sequences.
    Type: Grant
    Filed: June 25, 1993
    Date of Patent: June 11, 1996
    Assignee: Behringwerke AG
    Inventors: Charles G. Miyada, Teresa L. Born
  • Patent number: 5521300
    Abstract: Disclosed are nucleic acid oligonucleotides which are substantially complementary to nucleic acids from Mycobacteria, and subgeneric classes thereof. More specifically, the oligonucleotides are complementary to ribosomal RNA (rRNA) and the DNA encoding rRNA (rDNA). Uses for such oligonucleotides include detection of Mycobacteria by hybridization and amplification of Mycobacterial nucleic acid by polymerase chain reaction.
    Type: Grant
    Filed: August 13, 1991
    Date of Patent: May 28, 1996
    Assignee: Norval B. Galloway
    Inventors: Jyotsna S. Shah, Ray M. Nietupski, Jing Liu
  • Patent number: 5521295
    Abstract: Provided are hybrid receptor molecules wherein one domain of the receptor is derived from the cytokine superfamily of receptors and other domain is derived from a heterologous family of receptors. Also provided are methods for identifying ligands that bind to the hybrid receptor molecules.
    Type: Grant
    Filed: November 8, 1994
    Date of Patent: May 28, 1996
    Assignee: Amgen Inc.
    Inventors: Robert E. Pacifici, Arlen R. Thomason
  • Patent number: 5518884
    Abstract: Oligonucleotide probes and primers which exhibit M. kansasii-specificity in nucleic acid hybridization assays and in nucleic acid amplification reactions are provided. The full-length M. kansasii-specific sequence, identified herein as clone MK7, is 493 base pairs in length and has a GC content of 63%. Several M. kansasii-specific subsequences of MK7 are also provided. The probes and primers are useful in assays for species-specific detection and identification of M. kansasii.
    Type: Grant
    Filed: February 28, 1994
    Date of Patent: May 21, 1996
    Assignee: Becton, Dickinson and Company
    Inventors: Patricia A. Spears, Daryl D. Shank
  • Patent number: 5514786
    Abstract: Compositions and methods for modulating the activity of RNA are disclosed. In accordance with preferred embodiments, antisense compositions are prepared comprising targeting and reactive portions. The reactive portions preferably comprise one or two imidazole functionalities conjugated to the targeting oligonucleotide via linkers with or without intervening intercalating moieties. Therapeutics, diagnostics and research methods also are disclosed, as are synthetic nucleosides and nucleoside fragments that can be elaborated into oligonucleotides.
    Type: Grant
    Filed: September 10, 1992
    Date of Patent: May 7, 1996
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Phillip D. Cook, Thomas Bruice, Charles J. Guinosso, Andrew M. Kawasaki
  • Patent number: 5508167
    Abstract: Methods of diagnosing or prognosing Alzheimer's disease in a subject are disclosed. The methods involve directly or indirectly detecting the presence or absence of an apolipoprotein E type 4 (ApoE4) isoform or DNA, encoding ApoE4 in the subject. The presence of ApoE4 indicates the subject is afflicted with Alzheimer's disease or at risk of developing Alzheimer's disease. A novel immunochemical assay for detecting the presence or absence of the Apoliprotein E (ApoE) E4 allele in a subject is also disclosed.
    Type: Grant
    Filed: April 13, 1994
    Date of Patent: April 16, 1996
    Assignee: Duke University
    Inventors: Allen D. Roses, Warren J. Strittmatter, Guy S. Salvesen, Jan Enghild, Donald E. Schmechel
  • Patent number: 5501947
    Abstract: The invention provides oligonucleotides (A): and (B): and their derivatives. These oligos may be used as a pair of primers for the detection of HPV16 (SEQ ID NO:3) DNA in a sample, without false positives arising due to the presence of other HPV strains. Kits containing the primers and the use of the primers to screen populations are provided.
    Type: Grant
    Filed: March 12, 1993
    Date of Patent: March 26, 1996
    Assignee: Royal Free Hospital School of Medicine
    Inventors: Vincent C. Emery, Peggy J. Bavin, Patrick Walker
  • Patent number: 5500339
    Abstract: Method for determining the nucleotide base sequence of a double-stranded closed circular DNA. The method includes heating a solution which includes the DNA in the presence of at least 20% glycerol and/or ethylene glycol to at least 80.degree. C. to provide denatured DNA, and then sequencing the denatured DNA.
    Type: Grant
    Filed: March 30, 1993
    Date of Patent: March 19, 1996
    Assignee: Amersham Life Science, Inc.
    Inventors: Carl W. Fuller, Denise A. Pisa-Williamson
  • Patent number: 5489678
    Abstract: A synthetic strategy for the creation of large scale chemical diversity. Solid-phase chemistry, photolabile protecting groups, and photolithography are used to achieve light-directed spatially-addressable parallel chemical synthesis. Binary masking techniques are utilized in one embodiment. A reactor system, photoremovable protective groups, and improved data collection and handling techniques are also disclosed. A technique for screening linker molecules is also provided.
    Type: Grant
    Filed: February 16, 1995
    Date of Patent: February 6, 1996
    Assignee: Affymax Technologies N.V.
    Inventors: Stephen P. A. Fodor, Lubert Stryer, James L. Winkler, Christopher P. Holmes, Dennis W. Solas
  • Patent number: 5476775
    Abstract: Soil bacteria can be isolated which produce an enzyme capable of catalyzing the degradation of mannan-containing hemicellulose under conditions combining high pH and high temperature. Such bacteria can be cultured or used as sources of genetic information with which to engineer other microorganisms to produce the enzyme. Commercially useful quantities of native or recombinant hemicellulase can thus be produced by cultures consisting essentially of microorganisms capable of producing the enzyme.
    Type: Grant
    Filed: March 16, 1992
    Date of Patent: December 19, 1995
    Assignee: Chemgen Corporation
    Inventors: Douglas W. Fodge, David M. Anderson, Thomas M. Pettey